Cancer Research CR Mantle Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 50, 4332-4337, July 15, 1990]
© 1990 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borg, A.
Right arrow Articles by McGuire, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borg, A.
Right arrow Articles by McGuire, W. L.

HER-2/neu Amplification Predicts Poor Survival in Node-positive Breast Cancer1

Åke Borg2, Atul K. Tandon, Helgi Sigurdsson, Gary M. Clark, Mårten Fernö, Suzanne A. W. Fuqua, Dick Killander and William L. McGuire

Southern Swedish Breast Cancer Study Group, Department of Oncology, University Hospital, S-221 85 Lund, Sweden [Å. B., H. S., M. F., D. K.], and Department of Medicine/Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284-7884

HER-2/neu protooncogene amplification and protein expression were analyzed with slot blot and Western blot techniques, respectively, in more than 300 invasive primary breast tumors of all stages. Amplification (2- <30 copies) was found in 17% of these tumors and high expression was seen in 19%. There was a striking coincidence between gene amplification and high expression. Tumors associated with many involved axillary lymph nodes or with Stage IV disease were more often HER-2/neu amplified or overexpressed. Furthermore, gene alteration was strongly correlated with the absence of steroid receptors and with larger tumor size. High expression without gene amplification was seen in a minor subset of tumors of less aggressive character. Neither amplification nor overexpression was correlated with disease outcome for patients with negative axillary lymph nodes. For node-positive patients, however, HER-2/neu amplification was a significant predictor of early relapse and death (median follow-up = 45 months), and a similar trend, although not significant, existed for high gene expression. Multivariate analyses indicated that HER-2/neu alterations were not independent predictors of patient outcome.

1 Supported in part by Fru Berta Kamprads Foundation, John and Augusta Perssons Foundation, Swedish Cancer Society, NIH Grant CA 30195, and American Cancer Society Grant IN-11;61.

2 To whom reprint requests should be addressed.

Received 12/ 5/89. Revised 3/21/90.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
D. Lesniak, Y. Xu, J. Deschenes, R. Lai, J. Thoms, D. Murray, S. Gosh, J. R. Mackey, S. Sabri, and B. Abdulkarim
{beta}1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
Cancer Res., November 15, 2009; 69(22): 8620 - 8628.
[Abstract] [Full Text] [PDF]

Home page
 Am J Clin PatholHome page
F. Penault-Llorca, M. Bilous, M. Dowsett, W. Hanna, R. Y. Osamura, J. Ruschoff, and M. van de Vijver
Emerging Technologies for Assessing HER2 Amplification
Am J Clin Pathol, October 1, 2009; 132(4): 539 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. H. Choi, J. H. Ahn, S.-B. Kim, K.-H. Jung, G.-Y. Gong, M.-J. Kim, B.-H. Son, S.-H. Ahn, and W. K. Kim
Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis
Ann. Onc., August 1, 2009; 20(8): 1337 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist, April 1, 2009; 14(4): 320 - 368.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. E. Strecker, Q. Shen, Y. Zhang, J. L. Hill, Y. Li, C. Wang, H.-T. Kim, T. M. Gilmer, K. R. Sexton, S. G. Hilsenbeck, et al.
Effect of Lapatinib on the Development of Estrogen Receptor-Negative Mammary Tumors in Mice
J Natl Cancer Inst, January 21, 2009; 101(2): 107 - 113.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Chia, B. Norris, C. Speers, M. Cheang, B. Gilks, A. M. Gown, D. Huntsman, I. A. Olivotto, T. O. Nielsen, and K. Gelmon
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
J. Clin. Oncol., December 10, 2008; 26(35): 5697 - 5704.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Sihto, J. Lundin, T. Lehtimaki, M. Sarlomo-Rikala, R. Butzow, K. Holli, L. Sailas, V. Kataja, M. Lundin, T. Turpeenniemi-Hujanen, et al.
Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening
Clin. Cancer Res., July 1, 2008; 14(13): 4103 - 4110.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. Gomez, D. C. Doval, M. A. Chavez, P. C.-S. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W.C. Chow, M. C. Arbushites, et al.
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
J. Clin. Oncol., June 20, 2008; 26(18): 2999 - 3005.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M Hofmann, O Stoss, T Gaiser, H Kneitz, P Heinmoller, T Gutjahr, M Kaufmann, T Henkel, and J Ruschoff
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy
J. Clin. Pathol., January 1, 2008; 61(1): 89 - 94.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Moy and P. E. Goss
Lapatinib-Associated Toxicity and Practical Management Recommendations
Oncologist, July 1, 2007; 12(7): 756 - 765.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Moy and P. E. Goss
Lapatinib: Current Status and Future Directions in Breast Cancer
Oncologist, November 1, 2006; 11(10): 1047 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Souaze, S. Dupouy, V. Viardot-Foucault, E. Bruyneel, S. Attoub, C. Gespach, A. Gompel, and P. Forgez
Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression.
Cancer Res., June 15, 2006; 66(12): 6243 - 6249.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Morrison, V. Zanagnolo, N. Ramirez, D. E. Cohn, N. Kelbick, L. Copeland, L. G. Maxwell, and J. M. Fowler
HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients
J. Clin. Oncol., May 20, 2006; 24(15): 2376 - 2385.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Morrison, M. Radmacher, N. Mohammed, D. Suster, H. Auer, S. Jones, J. Riggenbach, N. Kelbick, G. Bos, and J. Mayerson
MYC Amplification and Polysomy 8 in Chondrosarcoma: Array Comparative Genomic Hybridization, Fluorescent In Situ Hybridization, and Association With Outcome
J. Clin. Oncol., December 20, 2005; 23(36): 9369 - 9376.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I.-M. Shih, J. J.-C. Sheu, A. Santillan, K. Nakayama, M. J. Yen, R. E. Bristow, R. Vang, G. Parmigiani, R. J. Kurman, C. G. Trope, et al.
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
PNAS, September 27, 2005; 102(39): 14004 - 14009.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Reedijk, S. Odorcic, L. Chang, H. Zhang, N. Miller, D. R. McCready, G. Lockwood, and S. E. Egan
High-level Coexpression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall Survival
Cancer Res., September 15, 2005; 65(18): 8530 - 8537.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. F. Press, G. Sauter, L. Bernstein, I. E. Villalobos, M. Mirlacher, J.-Y. Zhou, R. Wardeh, Y.-T. Li, R. Guzman, Y. Ma, et al.
Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials
Clin. Cancer Res., September 15, 2005; 11(18): 6598 - 6607.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. De Maria, M. Olivero, S. Iussich, M. Nakaichi, T. Murata, B. Biolatti, and M. F. Di Renzo
Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer
Cancer Res., February 1, 2005; 65(3): 907 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Chu, K. Blackwell, S. Chen, and J. Slingerland
The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer
Cancer Res., January 1, 2005; 65(1): 18 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein
Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
A. Millson, A. Suli, L. Hartung, S. Kunitake, A. Bennett, M. C. L. Nordberg, W. Hanna, C. T. Wittwer, A. Seth, and E. Lyon
Comparison of Two Quantitative Polymerase Chain Reaction Methods for Detecting HER2/neu Amplification
J. Mol. Diagn., August 1, 2003; 5(3): 184 - 190.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Oncologist, August 1, 2003; 8(4): 307 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. A. Dressman, A. Baras, R. Malinowski, L. B. Alvis, I. Kwon, T. M. Walz, and M. H. Polymeropoulos
Gene Expression Profiling Detects Gene Amplification and Differentiates Tumor Types in Breast Cancer
Cancer Res., May 1, 2003; 63(9): 2194 - 2199.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
W. Reed, B. Sandstad, R. Holm, and J. M. Nesland
The Prognostic Impact of Hormone Receptors and c-erbB-2 in Pregnancy-Associated Breast Cancer and Their Correlation with BRCAI and Cell Cycle Modulators
International Journal of Surgical Pathology, April 1, 2003; 11(2): 65 - 74.
[Abstract] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Konecny, G. Pauletti, M. Pegram, M. Untch, S. Dandekar, Z. Aguilar, C. Wilson, H.-M. Rong, I. Bauerfeind, M. Felber, et al.
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
J Natl Cancer Inst, January 15, 2003; 95(2): 142 - 153.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein
Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens
J. Clin. Oncol., July 15, 2002; 20(14): 3095 - 3105.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
D. J. Penington, I. Bryant, and D. J. Riese II
Constitutively Active ErbB4 and ErbB2 Mutants Exhibit Distinct Biological Activities
Cell Growth Differ., June 1, 2002; 13(6): 247 - 256.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Van Poznak, L. Tan, K. S. Panageas, C. D. Arroyo, C. Hudis, L. Norton, and A. D. Seidman
Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer
J. Clin. Oncol., May 1, 2002; 20(9): 2319 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. Simon, A. Nocito, T. Hubscher, C. Bucher, J. Torhorst, P. Schraml, L. Bubendorf, M. M. Mihatsch, H. Moch, K. Wilber, et al.
Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer
J Natl Cancer Inst, August 1, 2001; 93(15): 1141 - 1146.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. E. Jimenez, M. Hussain, F. J. Bianco Jr., U. Vaishampayan, P. Tabazcka, W. A. Sakr, J. E. Pontes, D. P. Wood Jr., and D. J. Grignon
Her-2/neu Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder: Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors
Clin. Cancer Res., August 1, 2001; 7(8): 2440 - 2447.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. Lyon, A. Millson, M. C. Lowery, R. Woods, and C. T. Wittwer
Quantification of HER2/neu Gene Amplification by Competitive PCR Using Fluorescent Melting Curve Analysis
Clin. Chem., May 1, 2001; 47(5): 844 - 851.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Hirano, M. Emi, M. Tsuneizumi, Y. Utada, M. Yoshimoto, F. Kasumi, F. Akiyama, G. Sakamoto, S. Haga, T. Kajiwara, et al.
Allelic Losses of Loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 Correlate with Postoperative Recurrence in Breast Cancer
Clin. Cancer Res., April 1, 2001; 7(4): 876 - 882.
[Abstract] [Full Text]

Home page
 Mol. Pathol.Home page
P N Nelson, G M Reynolds, E E Waldron, E Ward, K Giannopoulos, and P G Murray
Demystified ...: Monoclonal antibodies
Mol. Pathol., June 1, 2000; 53(3): 111 - 117.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
K. M. W. Ignatoski, A. J. LaPointe, E. H. Radany, and S. P. Ethier
erbB-2 Overexpression in Human Mammary Epithelial Cells Confers Growth Factor Independence
Endocrinology, August 1, 1999; 140(8): 3615 - 3622.
[Abstract] [Full Text]

Home page
 JCOHome page
T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt
Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
J. Clin. Oncol., July 1, 1999; 17(7): 1974 - 1974.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. S. Pandha, L.-A. Martin, A. Rigg, H. C. Hurst, G. W.H. Stamp, K. Sikora, and N. R. Lemoine
Genetic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial of erbB-2-Directed Suicide Gene Expression
J. Clin. Oncol., July 1, 1999; 17(7): 2180 - 2180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Scorilas, J. Yotis, C. Pateras, T. Trangas, and M. Talieri
Predictive Value of c-erbB-2 and Cathepsin-D for Greek Breast Cancer Patients Using Univariate and Multivariate Analysis
Clin. Cancer Res., April 1, 1999; 5(4): 815 - 821.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Jinno, M. G. Steiner, R. G. Mehta, M. P. Osborne, and N. T. Telang
Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide
Carcinogenesis, February 1, 1999; 20(2): 229 - 236.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Kawashima, V. Tsai, S. Southwood, K. Takesako, A. Sette, and E. Celis
Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2/neu by Primary in Vitro Immunization with Peptide-pulsed Dendritic Cells
Cancer Res., January 1, 1999; 59(2): 431 - 435.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross and J. A. Fletcher
The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
Oncologist, August 1, 1998; 3(4): 237 - 252.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
S. Gelmini, C. Orlando, R. Sestini, G. Vona, P. Pinzani, L. Ruocco, and M. Pazzagli
Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification
Clin. Chem., May 1, 1997; 43(5): 752 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
M. Noguchi, N. Koyasaki, N. Ohta, H. Kitagawa, M. Earashi, M. Thomas, I. Miyazaki, and Y. Mizukami
Internal Mammary Nodal Status Is a More Reliable Prognostic Factor Than DNA Ploidy and c-erb B-2 Expression in Patients With Breast Cancer
Arch Surg, February 1, 1993; 128(2): 242 - 246.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.